pd checkpoint inhibitor immune ctla anti received inhibitors treatment prior 
pd anti agent received prior therapy treatment merck participated pembrolizumab 
pd prior therapy treatment inhibitor anti ctla received patients pathway 
anti ctla adverse pd effects immune weeks dose ctcae met 
pd durvalumab including inhibitor previous tremelimumab ctla treatment anti pdl 
anti pd ctla prior checkpoint pdl cd antibody immune antibodies 
checkpoint immune inhibitor inhibitors prior therapy treatment blockade immunotherapy therapies